CTLA4 and non-small cell lung carcinoma: Therapies targeting the inhibitory checkpoints CTLA-4 and PD-1 axis induce prominent anti-tumor responses and lasting clinical benefit in patients with different tumor types, including non-small cell lung cancer (NSCLC).